Evidence map›Paper›PMID 29805553›Full record

ReviewOncology letters2018

Recent advances in CD8

Yating Yu, Xinbo Ma, Rufei Gong, Jianmeng Zhu, Lihua Wei, Jinguang Yao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. CD8Nature communications · 2022
    Trial
  2. Article
  3. The roles and heterogeneity of CD8International journal of molecular medicine · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Circulating CD8BMC cancer · 2022
    Article
  15. CD8International journal of molecular sciences · 2022
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yating YuDepartment of Medical School, Guangxi University of Science and Technology, Liuzhou, Guangxi 545005, P.R. China.
Xinbo MaDepartment of Medical School, Guangxi University of Science and Technology, Liuzhou, Guangxi 545005, P.R. China.
Rufei GongDepartment of Medical School, Guangxi University of Science and Technology, Liuzhou, Guangxi 545005, P.R. China.
Jianmeng ZhuDepartment of Chunan First People's Hospital, Hangzhou, Zhejiang 310000, P.R. China.
Lihua WeiDepartment of Medical School, Guangxi University of Science and Technology, Liuzhou, Guangxi 545005, P.R. China.
Jinguang YaoDepartment of Medical School, Guangxi University of Science and Technology, Liuzhou, Guangxi 545005, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various subgroups of CD8

Indexed as

autoimmune diseaseCD8+ regulatory T cellsCD8αα+immune regulationQa-1

Identifiers

PMID29805553
PMCPMC5950136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.